文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

全球统一剂量指数(gUDI)用于评估前列腺癌同步整合推量放疗计划

A global Unified Dosimetry Index (gUDI) to evaluate simultaneous integrated boost radiotherapy plans in prostate cancer.
PubMed 文献 · Radiother Oncol · 2018-06-23

该研究提出全球统一剂量指数(gUDI),用于评估前列腺癌同步整合推量容积旋转调强放疗计划(36.25 Gy/5次照射全前列腺,37.5 Gy/5次照射优势前列腺内病灶)。对65例患者评估显示,前列腺剂量梯度、前列腺适形性和DIL适形性指数偏离理想值较大,多数计划被评为「中等」和「良好」。

要点

  • gUDI整合了剂量覆盖、适形性、均匀性和剂量梯度指数,可评估不同处方剂量体积的放疗计划。
  • 65例前列腺癌患者中,前列腺剂量梯度、前列腺适形性和DIL适形性指数偏离理想值较大。
  • gUDI分类显示多数计划评为「中等」和「良好」。

核心结论

  • gUDI评分可作为量化治疗计划质量的工具,即使治疗不同处方剂量的体积时也适用。

研究设计与样本

  • 研究纳入65例前列腺癌患者,评估同步整合推量容积旋转调强放疗计划(全前列腺36.25 Gy/5次,优势前列腺内病灶37.5 Gy/5次)。

主要发现

  • 前列腺剂量梯度、前列腺适形性和DIL适形性指数偏离理想值较大。
  • gUDI指数分类显示多数计划评为「中等」和「良好」。

关键数值与推荐

  • 计划可排序为「优秀」、「良好」、「中等」或「差」。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Formulation of a global Unified Dosimetry Index (gUDI) for the evaluation of prostate simultaneous integrated boost Volumetric Modulated Arc Therapy (VMAT by RapidArc) radiotherapy plans. METHODS AND MATERIALS: Dose coverage, conformity, homogeneity and dose gradient index could be included in the Unified Dosimetry Index (UDI). We developed a global UDI to evaluate treatment plans containing volumes irradiated with different dose prescriptions: Intensity Modulated Radiation Therapy with simultaneous integrated boost (IMRT-SIB) with 2 dose levels (36.25 Gy/5 fz for the whole prostate gland and 37.5 Gy/5 fz for Dominant Intraprostatic Lesion (DIL)). To validate gUDI scoring system, 65 prostate cancer patients were evaluated. Mean (µ) and standard deviations (σ) were calculated for all dosimetry indices and gUDI. Furthermore, gUDI µ and σ were analyzed to compare and classify treatment plans: plans can be ranked as "excellent", "good", "average" or "poor". RESULTS: Prostate Dose Gradient, Prostate Conformity and DIL Conformity indices had highlighted a major deviation from ideal scores. gUDI index classification showed most of the plans scored as "average" and "good". CONCLUSION: gUDI score can be a useful tool to quantify treatment plans quality also when volumes with different dose-prescription are treated.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Mambretti M, Romanò C, Marvaso G, et al. A global Unified Dosimetry Index (gUDI) to evaluate simultaneous integrated boost radiotherapy plans in prostate cancer. Radiother Oncol. 2018. PMID: 29945720. doi:10.1016/j.radonc.2018.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。